Our Therapies

HEMLIBRA® Injection Therapy

Violet Health Outpatient Specialty Infusion Care

About HEMLIBRA® Injection Therapy

HEMLIBRA® (emicizumab-kxwh) is a bispecific antibody, and that word is doing real work. Most antibodies bind one target. This one has two arms that grab two different clotting proteins, factor IXa and factor X, and hold them together in the position where factor VIII would normally bring them. In hemophilia A, factor VIII is missing or does not work. HEMLIBRA® does not replace it. It stands in for the job it does.

That distinction matters more than it sounds. Because emicizumab bears no structural resemblance to factor VIII, it works equally well in patients who have developed inhibitors, the neutralizing antibodies that make factor replacement fail. Inhibitors develop in roughly a third of people with severe hemophilia A, and for decades they were the hardest problem in the field. HEMLIBRA® sidesteps the problem rather than solving it, and the dose is the same whether inhibitors are present or not.

This is prophylaxis, not rescue

HEMLIBRA® is given to prevent bleeds, not to stop one that has already started. It will not treat a breakthrough bleed and it does not cover surgery on its own. Every patient stays supplied with factor VIII or a bypassing agent for those situations and needs a written plan for using them. This is the single most important thing to understand about the drug, and it is where expectations most often go wrong.

Dosing and administration

Loading dose: 3 mg/kg once weekly for the first 4 weeks. Every patient receives this, regardless of which maintenance schedule follows.
Maintenance, starting at week 5, is one of three options: 1.5 mg/kg once weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks.
All three maintenance schedules produce comparable bleed protection. The choice is a practical one, and patients can move between them.
Given as a subcutaneous injection into the abdomen, the outer upper arm, or the thigh. No IV, no port, no infusion chair.
Approved from birth onward. Dosing is weight-based at every age, so pediatric doses are recalculated as children grow.

Doses are drawn from single-dose vials in four strengths: 30 mg, 60 mg, 105 mg, and 150 mg. More than one vial of the same concentration can be combined to make up a dose, but vials of different concentrations should never be mixed in a single syringe.

Most patients inject at home

This is the most self-directed therapy we offer. After training, patients or caregivers give the injections themselves, and a subcutaneous dose takes seconds rather than hours. Our role is training, dose calculation as weight changes, laboratory monitoring with the right assays, and being the place to call when something changes. Patients who would rather come in are welcome to, and many do during the loading phase.

The laboratory interference is not a footnote

Emicizumab normalizes the aPTT, because it mimics factor VIII in the test tube just as it does in the body. A normal aPTT on HEMLIBRA® does not mean normal hemostasis. Every clotting test that depends on the intrinsic pathway becomes unreliable: aPTT, one-stage factor VIII activity, aPTT-based activated protein C resistance, and clotting-based Bethesda assays for inhibitor titers. Chromogenic assays using bovine reagents are unaffected, and those are the ones to order. This matters most in an emergency department, where a normal aPTT in a hemophilia patient is easy to misread as reassurance.

Conditions treated by this therapy

HEMLIBRA® has a single FDA-approved indication, stated broadly:

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients, from newborn onward, with hemophilia A (congenital factor VIII deficiency), with or without factor VIII inhibitors.

The breadth is the notable part. There is no age floor, no inhibitor requirement, and no severity threshold written into the indication, which is unusual among the therapies on this site.

Who this therapy is not for

Patients seeking on-demand treatment. HEMLIBRA® is prophylaxis only. Breakthrough bleeds and surgical coverage still require factor VIII or a bypassing agent.
Hemophilia B, which is a factor IX deficiency. Emicizumab does nothing for it, since factor IXa is one of the proteins it binds rather than the one that is missing.
Acquired hemophilia A, von Willebrand disease, or other bleeding disorders. The indication is congenital factor VIII deficiency specifically.
Patients undergoing immune tolerance induction. Safety and efficacy in that setting have not been established, so concurrent use is a prescriber decision that should be stated explicitly on the referral.
Patients with known hypersensitivity to emicizumab-kxwh or any component of the formulation. This is the only contraindication on the label.

One point that is easy to miss: HEMLIBRA® does not eradicate an inhibitor or restore a response to factor VIII. A patient with an inhibitor still has one, and factor replacement will still fail, which is why the breakthrough bleed plan for those patients calls for a bypassing agent rather than factor.

HEMLIBRA® Price

The cost of prescription medications can vary depending on your insurance coverage. If you're concerned about the price of your medication:

Contact your insurance provider to understand your coverage
Ask your doctor or pharmacist about lower-cost alternatives
Check with the drug manufacturer about financial assistance programs
Explore patient assistance options if you're uninsured or underinsured

Remember, many resources exist to help patients access necessary medications. Don't hesitate to ask for help if you're struggling with medication costs. No patient should go without necessary treatment due to financial limitations. If you have questions about financial assistance opportunities, contact a member of our Violet Health team.

What to Expect During HEMLIBRA® Injection Therapy

HEMLIBRA® is a prescription subcutaneous injection, first approved by the FDA in 2017 for hemophilia A with inhibitors and broadened in 2018 to cover patients with or without them. At Violet Health we handle training, dose calculation, and monitoring, and we can give the injection here for patients who would rather not do it themselves.

Your first visit is mostly about learning. Here is how it runs:

Weight is taken and the dose calculated. Every dose in the loading and maintenance schedule follows from that number.
Baseline labs are drawn using chromogenic assays, since standard clotting tests stop being interpretable once treatment begins.
You or your caregiver are trained on technique, site rotation, vial handling, and how to combine vials when a dose needs more than one.
The injection itself takes a few seconds. Plan on 45 minutes to an hour for a first visit, and considerably less after that.
There is no premedication, no observation period, and no reason you cannot drive yourself home.

Injection sites are the abdomen, the outer upper arm, or the thigh, rotated each time. The upper arm and thigh are usually easier when a caregiver is giving the injection. Avoid skin that is bruised, red, tender, or hardened, which in this population also means steering clear of any area where a bleed is resolving.

The loading phase

The first four weeks are weekly at 3 mg/kg no matter which maintenance schedule you are headed toward. Protective levels build over that period rather than arriving with the first dose, so keep your bleed treatment plan close at hand through loading and beyond. Nothing about starting HEMLIBRA® changes what you do when a bleed happens.

Choosing and changing your schedule

Weekly, every two weeks, and every four weeks all deliver similar protection, which makes this one of the few genuinely free choices in treatment. Many patients start weekly and stretch the interval once they are comfortable with the injection. Others prefer monthly from the outset. Switching later is straightforward.

What success looks like

In the HAVEN trials, prophylaxis reduced annualized bleed rates by roughly 68% to 87% compared with prior treatment, and a substantial share of patients had no treated bleeds at all. The benefit is measured in bleeds that did not happen, which is harder to feel than a symptom improving. Keeping a bleed log is genuinely useful here, both for you and for the team adjusting your plan.

Carry documentation

Carry a card or record stating that you are on HEMLIBRA®. If you need urgent care anywhere else, the treating clinician has to know two things: your aPTT will read normal regardless of your actual bleeding risk, and the choice of bypassing agent is not routine. Both are easy to get wrong without that context.

Boxed Warning: Thrombotic Microangiopathy and Thromboembolism

HEMLIBRA® carries a boxed warning, and it is unusual in describing a risk from a drug combination rather than from HEMLIBRA® by itself.

Cases of thrombotic microangiopathy and thrombotic events were reported when, on average, a cumulative amount of more than 100 U/kg per 24 hours of activated prothrombin complex concentrate (aPCC, sold as FEIBA®) was given for 24 hours or more to patients receiving HEMLIBRA® prophylaxis. Monitor for thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend HEMLIBRA® if symptoms occur.

What this means in practice

aPCC is the agent of concern. If a bypassing agent is needed for a breakthrough bleed, recombinant factor VIIa is generally preferred.
If aPCC cannot be avoided, it should begin at no more than 50 U/kg, with laboratory monitoring and clinical oversight if more is required.
Symptoms of thrombotic microangiopathy include confusion, weakness, swelling of the arms and legs, yellowing of the skin or eyes, abdominal pain, nausea, vomiting, and a drop in urine output.
Every patient on HEMLIBRA® needs a written breakthrough bleed plan that names the agent, the dose, and the ceiling. Where this warning turns into harm, it is almost always because that plan was missing or because an urgent care team never saw it.

HEMLIBRA® Side Effects

The side effect profile is mild by the standards of most therapies offered here. The most common reactions, reported in 10% or more of patients in clinical trials, were:

Injection site reactions
Headache
Joint pain

Other reported reactions include fever, diarrhea, muscle pain, and fatigue.

Injection site reactions

These are the most frequent and almost always local and self-limited: redness, discomfort, itching, or a small area of firmness that settles within a day or two. Rotating sites helps. Letting a refrigerated vial come to room temperature before injecting helps more than most people expect. No infusion page in this set has this category at all, so it is worth saying plainly that a sore spot after an injection is not a bleed.

Thrombotic events

Separate from the boxed warning, thrombotic events have been reported. Report swelling, pain, redness, or warmth in an arm or leg, chest pain, shortness of breath, or coughing up blood. A condition that has defined your life as a bleeding risk now carries a small clotting risk, which takes some adjusting to.

Antibodies to emicizumab

Anti-emicizumab antibodies were reported in about 5% of patients in clinical trials. Most had no change in their response, but a small number developed antibodies that reduced the drug's effect, which shows up as a loss of bleed control rather than as a symptom. A rising bleed rate after a stretch of good control is worth reporting rather than waiting out.

Hypersensitivity

Rash, hives, and angioedema have been reported. Severe hypersensitivity is uncommon, but because most doses are given at home rather than in a monitored setting, patients should know what a serious reaction looks like and when to call emergency services instead of the clinic.

Call your care team right away if you experience:

Confusion, weakness, swelling of the arms or legs, yellowing of the skin or eyes, or a drop in urine output
Severe or persistent abdominal pain, nausea, or vomiting
Pain, swelling, warmth, or redness in an arm or leg
Chest pain, difficulty breathing, or coughing up blood
A bleed that does not respond as expected, or bleeds that are becoming more frequent
Severe rash, facial swelling, or difficulty breathing after an injection

Important Safety Information

HEMLIBRA® has no contraindications other than known hypersensitivity to emicizumab-kxwh or any component of the formulation. The cautions that matter are about what is given alongside it, and about how it changes laboratory results.

Bypassing agents and factor VIII

Prophylactic bypassing agents are discontinued the day before HEMLIBRA® prophylaxis begins.
Prophylactic factor VIII may be continued during the first week of HEMLIBRA® loading.
For breakthrough bleeds, use the lowest effective dose of bypassing agent, with recombinant factor VIIa generally preferred over aPCC.
Safety and efficacy have not been established in patients undergoing immune tolerance induction.

Laboratory tests affected

Emicizumab interferes with every coagulation test that relies on the intrinsic pathway. Unreliable while on treatment: aPTT, one-stage factor VIII activity, aPTT-based activated protein C resistance, clotting-based Bethesda assays for factor VIII inhibitor titers, and any single-factor assay based on aPTT.

Unaffected and usable: chromogenic factor VIII activity using bovine reagents, chromogenic or immunologic Bethesda assays using bovine reagents, thrombin time, prothrombin time and INR, D-dimer, and single-factor assays based on the prothrombin time.

The aPTT normalizes on HEMLIBRA® and stays normal. That result should not be used to assess bleeding risk, to guide factor dosing, or to reassure anyone in an emergency department. Because emicizumab has a long half-life, the interference persists for up to six months after the last dose.

Pregnancy and breastfeeding

There are no adequate data on HEMLIBRA® in pregnancy. Females of reproductive potential should use effective contraception during treatment. Whether emicizumab passes into human milk is not known. Hemophilia A is X-linked and affects males predominantly, so this applies to a smaller share of patients here than on most of our pages, though symptomatic carriers with low factor VIII levels are treated and should not be overlooked in counseling.

Storage and handling

Store vials in the refrigerator at 36°F to 46°F in the original carton. Do not freeze and do not shake.
Unopened vials may be kept at room temperature for up to 7 days, then returned to the refrigerator if needed.
Let a refrigerated vial reach room temperature before injecting. A cold injection stings considerably more.
Vials are single-dose and preservative-free. Discard any unused portion, and never combine vials of different concentrations in one syringe.

If a dose is missed, give it as soon as possible before the next scheduled dose, then resume the usual schedule. Do not give two doses on the same day to make up for a missed one.

What Your Referral Should Include

HEMLIBRA® referrals turn on a few specifics that are easy to leave out, particularly the bleed plan and the assay method used for inhibitor testing. A complete referral keeps things moving. Please include:

Confirmed hemophilia A diagnosis with baseline factor VIII activity and severity classification
Inhibitor status with current titer and the assay method used. A clotting-based Bethesda result drawn after HEMLIBRA® has started cannot be interpreted, so baseline testing has to come first
Current weight with the date taken, since every dose is weight-based, and for pediatric patients a plan for how often weight will be rechecked and the dose recalculated
Which maintenance schedule is intended: 1.5 mg/kg weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks
Current prophylaxis regimen, whether factor VIII or a bypassing agent, with the planned stop date. Prophylactic bypassing agents stop the day before HEMLIBRA® begins
The breakthrough bleed treatment plan in writing, naming the agent, the dose, and the maximum, with explicit guidance on aPCC. This is the item most often missing
Whether the patient is receiving or being considered for immune tolerance induction
Bleed history over the past 12 months, including treated bleeds, joint bleeds, and any target joints
Baseline joint assessment or imaging where available, and any planned orthopedic or dental procedures
History of thrombotic events, or risk factors for them
Prior exposure to emicizumab, including any period of discontinuation and the reason for it
Whether the patient or caregiver will self-inject or prefers administration here, and what training is needed
The hemophilia treatment center managing overall care, and who to contact for bleed events
Pregnancy status and contraception plan for females of reproductive potential, including symptomatic carriers
Confirmation of specialty pharmacy arrangement and payer authorization, since HEMLIBRA® is dispensed rather than administered under a buy-and-bill model